Breast Implant–Associated Malignancies: Current Recommendations for Workup and Management

View at publisher
Authors: Megan Fracol, Roberto N. Miranda, Anne S. Tsao, Megan M. Rodriguez, Loretta J. Nastoupil, Patricia A. Young, Andy Sherrod, Danielle M. LeBlanc, Lisa M. Hunsicker, Carlos E. Bacchi, Thiago Gabriel, Terence M. Myckatyn
+11 more Shoichiro Tanaka, Lauren Kuykendall, Erika Resetkova, Mark G. Evans, Puja Jagasia, Colleen M. McCarthy, Fabio Santanelli di Pompeo, Kelly K Hunt, L Jeffrey Medeiros, Cara Haymaker, Mark W. Clemens
Cited by: 3
References: 62

Abstract

LEARNING OBJECTIVES: After studying this article, the participant should be able to: 1. Name the 3 major subtypes of breast implant-associated (BIA) malignancies. 2. Recognize the most common presenting symptoms of BIA malignancies. 3. Identify appropriate treatment options for each BIA malignancy, including chemotherapy, radiation, and surgery. 4. Answer patient questions about recurrence and reconstruction after a diagnosis of BIA malignancy. SUMMARY: Although rare, breast implants have been associated with several malignancies, categorized into 3 major subtypes: BIA anaplastic large-cell lymphoma, B-cell lymphoma, and squamous cell carcinoma. BIA anaplastic large-cell lymphoma is the most common subtype, with more than 1700 cases reported to date. BIA squamous cell carcinoma is the most aggressive subtype. The most common presenting symptom is late seroma. Patients typically report pain and swelling. Workup should begin with an ultrasound or mammography, and any fluid collections should be aspirated and evaluated in conjunction with pathology. The authors provide an algorithm for surgical excision and adjuvant treatment based on disease stage and subtype.

Fields of Study & Subjects

Breast Implant and Reconstruction Breast Cancer Treatment Studies Organ and Tissue Transplantation Research

Publication details

Journal / source
Plastic & Reconstructive Surgery
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
157
Issue
5
Pages
774e–784e
Publication date
29 April 2026
Language
EN